Исследуемый тройной агонист рецепторов GIP/GLP-1/глюкагона (LY3437943) компании Eli Lilly, изучаемый в исследованиях фазы 3; нигде не одобрен как лекарственный препарат и не предназначен для терапевтического применения у человека.
Клиническая стадияЛиофилизированный флаконТакже известен как:LY3437943 · Triple Receptor Agonist · Triple G
Приблизительно 6 дней (человек; Urva et al. 2022, фаза 1b)
Хранение
Лиофилизированный порошок при температуре ниже −15 °C, в плотно закрытом флаконе, в защищённом от света месте; перед вскрытием дать запечатанному флакону нагреться до комнатной температуры. Восстановленные флаконы — 2–8 °C.
Размеры
5 mg, 10 mg
Что это
Соединение. Происхождение, исследования и регуляторная реальность.
Retatrutide (development code LY3437943) is an investigational triple hormone-receptor agonist developed by Eli Lilly: a single synthetic peptide engineered to activate the GIP, GLP-1 and glucagon receptors. As of September 2026 it has not been approved as a medicine in any jurisdiction; Lilly states it is available only to participants in its clinical trials.
A Phase 1b multiple-ascending-dose study (Urva et al., 2022) characterised its pharmacokinetics, and a Phase 2 trial (Jastreboff et al., 2023) examined its triple-receptor mechanism and dose-dependent effect on body weight in adults with obesity. The Phase 3 TRIUMPH programme is evaluating retatrutide in obesity and related conditions.
The FDA states that retatrutide cannot be used in compounding under federal law and is not a component of any FDA-approved drug, and it has warned telehealth companies, distributors and outsourcing facilities that sold unapproved retatrutide falsely labelled ‘for research purposes’ or ‘not for human consumption’. Research-use-only vials sold commercially are outside Lilly’s clinical-trial supply chain and have not been reviewed for safety, effectiveness or quality.
Живой реестр поставщиков · сортировано по цене
Каждый поставщик. То же соединение, отсортировано по возрастанию.
RETATRUTIDE · нормализовано по цене
Предложений: 1 · сначала поставщики без предупреждений
01
QSC PeptidesВыборVID-QSC-PEPT · набор 20 фл. · $430
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
It is not an approved medicine anywhere and the FDA states it cannot be used in compounding under federal law. Products sold research-use-only are for laboratory research, not human use; RUO labelling does not authorise personal use.
How is research-vial retatrutide different from a pharmacy product?
There is no approved pharmacy product to compare it with: retatrutide is investigational. Lilly states it is available only to its clinical-trial participants, so any vial sold commercially sits outside that controlled chain.
What should a CoA show for retatrutide?
HPLC purity, an LC-MS mass that matches the developer-published structure (vendor pages have been seen listing wrong CAS numbers and masses for this compound), a lot number, an independent third-party lab name and a test date.